Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Multiple Myeloma 8Prostatic Neoplasms 6Neoplasms, Plasma Cell 6Sarcoma 5Neoplasms 5Melanoma 4Liver Neoplasms 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Hepatocellular 4Lymphoma, Follicular 3Leukemia 3Carcinoma, Renal Cell 3Brain Neoplasms 3Myelodysplastic Syndromes 2Lymphoma 2Kidney Neoplasms 2HIV Infections 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Acquired Immunodeficiency Syndrome 2Waldenstrom Macroglobulinemia 1Urologic Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Stomatitis, Aphthous 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Endometrial Stromal 1Recurrent Uterine Corpus Sarcoma 1Rectal Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1

Interventions

pazopanib 1ixabepilone 1Thalidomide 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Recurrent Uterine Corpus Sarcoma × Thalidomide × Clear all
NCT00025220 2019-07-23

Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡